GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ambu A/S (OTCPK:AMBFF) » Definitions » EBIT

Ambu A/S (Ambu A/S) EBIT : $70.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ambu A/S EBIT?

Ambu A/S's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $28.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $70.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ambu A/S's annualized ROC % for the quarter that ended in Mar. 2024 was 10.23%. Ambu A/S's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 37.08%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ambu A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.50%.


Ambu A/S EBIT Historical Data

The historical data trend for Ambu A/S's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambu A/S EBIT Chart

Ambu A/S Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.88 55.42 52.84 18.76 38.78

Ambu A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.62 12.95 9.73 18.87 28.86

Competitive Comparison of Ambu A/S's EBIT

For the Medical Devices subindustry, Ambu A/S's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambu A/S's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ambu A/S's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ambu A/S's EV-to-EBIT falls into.



Ambu A/S EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $70.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ambu A/S  (OTCPK:AMBFF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ambu A/S's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=113.124 * ( 1 - 22.99% )/( (847.72 + 855.272)/ 2 )
=87.1167924/851.496
=10.23 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1000.468 - 112.22 - ( 40.528 - max(0, 123.925 - 293.205+40.528))
=847.72

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1029.33 - 117.642 - ( 56.416 - max(0, 129.158 - 326.54+56.416))
=855.272

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ambu A/S's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=115.456/( ( (172.207 + max(133.141, 0)) + (172.162 + max(145.194, 0)) )/ 2 )
=115.456/( ( 305.348 + 317.356 )/ 2 )
=115.456/311.352
=37.08 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(93.638 + 132.118 + 20.483) - (112.22 + 0 + 0.878)
=133.141

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(108.458 + 134.115 + 21.137) - (117.642 + 0 + 0.874)
=145.194

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ambu A/S's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=70.42/4704.341
=1.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ambu A/S EBIT Related Terms

Thank you for viewing the detailed overview of Ambu A/S's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambu A/S (Ambu A/S) Business Description

Address
Baltorpbakken 13, Ballerup, DNK, DK-2750
Ambu A/S is a Denmark based company providing single-use flexible endoscopes and is dedicated to optimizing hospital workflows and improving patient care. The company has created medtech solutions like resuscitators, anaesthesia masks, and electrodes and operates R&D, manufacturing and sales in Europe, North America and the Asia Pacific.

Ambu A/S (Ambu A/S) Headlines

From GuruFocus

Q4 2023 Ambu A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2021 Ambu A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2022 Ambu A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Ambu A/S Appointment of New CEO Call Transcript

By GuruFocus Research 02-12-2024

Q1 2023 Ambu A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Ambu A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-12-2024

Q3 2021 Ambu A/S Guidance Call Transcript

By GuruFocus Research 02-12-2024

Q2 2022 Ambu A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Ambu A/S Corporate Analyst Meeting Transcript

By GuruFocus Research 02-12-2024